STOCK TITAN
  1. Home
  2. Sec-filings
  3. SPRY
  4. [SCHEDULE 13D/A] ARS Pharmaceuticals, Inc. SEC Filing

[SCHEDULE 13D/A] ARS Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock SPRY logo
ARS Pharms

NASDAQ:SPRY

SPRY Rankings

#2614 Ranked by Market Cap
N/A Ranked by Dividends

SPRY Latest News

Oct 8, 2025
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
Sep 29, 2025
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
Sep 19, 2025
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
Sep 8, 2025
Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
Aug 28, 2025
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

SPRY Latest SEC Filings

Sep 29, 2025
[8-K] ARS Pharmaceuticals, Inc. Reports Material Event
Aug 27, 2025
[8-K] ARS Pharmaceuticals, Inc. Reports Material Event
Aug 22, 2025
[Form 4] ARS Pharmaceuticals, Inc. Insider Trading Activity
Aug 22, 2025
[Form 4] ARS Pharmaceuticals, Inc. Insider Trading Activity
Aug 21, 2025
[Form 4] ARS Pharmaceuticals, Inc. Insider Trading Activity

SPRY Stock Data

1.14B
73.77M
16.83%
86.19%
21.29%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO